Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001902975 | SCV002165830 | uncertain significance | Amyotrophic lateral sclerosis type 21 | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 792 of the MATR3 protein (p.Ile792Val). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 1396414). This variant has not been reported in the literature in individuals affected with MATR3-related conditions. This variant is present in population databases (rs766453846, gnomAD 0.02%). |
Ambry Genetics | RCV004641753 | SCV005137280 | uncertain significance | Inborn genetic diseases | 2024-03-21 | criteria provided, single submitter | clinical testing | The c.2374A>G (p.I792V) alteration is located in exon 17 (coding exon 13) of the MATR3 gene. This alteration results from a A to G substitution at nucleotide position 2374, causing the isoleucine (I) at amino acid position 792 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |